Postings

AbbVie—Allergan merger a bad deal for consumers
As the Federal Trade Commission signs off on the $63 billion deal between AbbVie and Allergen, advocates warn that the merger will reduce competition in a number of markets where AbbVie and Allergan directly overlap with each other. The deal will also exacerbate competitive problems that already exist in the pharmaceutical drug industry relating to rebate walls and patent abuses.

All insurers must make coronavirus tests and treatment free to patients
Americans have been urged to seek medical help if they are showing symptoms of COVID-19, but out-of-pocket costs could put insured patients into serious medical debt, or worse, deter them from seeking treatment at all — causing undue suffering and death, and exacerbating the pandemic. A coalition of more than 80 advocacy groups came together to urge all health insurance corporations to waive all patient fees for care associated with COVID-19, including copays and deductibles.

Affordability should be paramount when the COVID-19 vaccine is released to the public
Consumer Action joined nearly 70 organizations in writing to President Trump, asking him to ensure that vaccines or treatments for the coronavirus disease (COVID-19), developed and purchased with U.S. taxpayer dollars, are reasonably priced and available to everyone. Americans will not accept President Trump allowing Big Pharma corporations to profit off a pandemic that continues to claim thousands of lives.

Congress: Pass a clean budget for FY2021
Advocates called on Congress to pass an upcoming federal budget that funds the things that Americans care about, not undo essential consumer and environmental safeguards through policy riders. Policy riders are attached to legislation and rarely have anything to do with the bill. In fact, most riders are handouts to big corporations and special favors for interest groups that could not become law on their own merits. As Congress prepares the federal budget for fiscal year 2021, no appropriations titles, package of bills, or continuing resolutions should pass if they contain poison pill policy riders that go against the public interest, including policies that ensure safe and healthy food, restrain Wall Street abuses, provide access to justice and fair housing, and guarantee access to safe healthcare.

Pharmacy benefit managers are driving up drug costs for patients
States, local governments, organizations, and businesses use pharmacy benefit managers (PBMs) to negotiate lower drug prices for the individuals on their health insurance plans. Three organizations control 85 percent of this market. While PBMs play a crucial role in the drug supply chain, the lack of transparency regarding their practices has long contributed to the rising cost of prescription drugs. The PBM Transparency and Prescription Drug Costs Act (H.R. 5304) will increase transparency, hold pharmacy benefit managers (PBMs) accountable, and help lower prescription drug prices. This bipartisan bill will mandate quarterly reports on the costs, fees, and rebate information associated with PBM contracts. This reform ensures employers know the true costs of the services they are paying for and passes on savings to consumers.

The sale of .org a big concern for non-profit organizations
A private equity firm will soon run the internet’s top domain name extension for non-profits after purchasing the non-profit organization that runs it. Millions of non-profits around the world rely on .org domain. Yet, the Internet Society, the American nonprofit organization founded in 1992 to provide leadership in internet-related standards, decided to sell it, causing concern that fees to renew domain names will drastically increase in order for the firm to recoup its billion-dollar investment. Proponents of the deal reasoned that competition will keep renewal prices in check, but non-profit associations with established web addresses are wary to risk changing their web address and losing their online identity—in doing so, organizations may not be found by clients and donors under a new web address.

Healthcare mergers result in less choice and higher prescription drug prices for consumers
As the Federal Trade Commission considers signing off on the $63 billion deal between AbbVie and Allergen, advocates warn that the merger will reduce competition in a number of markets where AbbVie and Allergan directly overlap with each other. The deal will also exacerbate competitive problems that already exist in the pharmaceutical drug industry relating to rebate walls and patent abuses.

The CREATES Act protects patients from outrageous prescription drug costs
When it comes to prescription medicines, patients win when companies innovate new cures and treatments. Patients also win when more affordable generic versions of those medicines enter the market. Unfortunately, some drug manufacturers aren’t playing by the rules.

Trump administration to roll back fuel efficiency requirements
In comments to the Environmental Protection Agency, coalition advocates argue that the cuts outlined in Trump administration’s so-called Safe and Affordable Fuel Efficient rule, pose a threat to public safety by weakening Clean Air standards and driving up costs for consumers—harming low-income households the most with higher fuel costs, while driving up asthma rates and premature deaths.

3M seniors could lose critical benefits if Benchmark Cap remains in Medicare Advantage
Three million American seniors are at risk of being denied critically important benefits like care coordination, vision, dental, hearing, and wellness programs if Congress allows the benchmark cap to stay in place. In a letter to Congress, coalition advocates supported the bipartisan Improving Seniors Access to Quality Benefits Act (HR 4952), which aims to lift the benchmark cap, thus giving beneficiaries higher-quality care.

Search

Quick Menu

Facebook FTwitter T
 

Consumer Help Desk

Advocacy